These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 21541818)

  • 1. Safety of regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic kidney disease patients not on hemodialysis.
    Palani G; Husain Z; Salinas RC; Karthikeyan V; Karthikeyan AS; Ananthasubramaniam K
    J Nucl Cardiol; 2011 Aug; 18(4):605-11. PubMed ID: 21541818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemodynamic response, arrhythmic risk, and overall safety of regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic obstructive pulmonary disease and bronchial asthma patients.
    Husain Z; Palani G; Cabrera R; Karthikeyan AS; Dhanalakota S; Pathmanathan S; Jacobsen G; Ananthasubramaniam K
    Int J Cardiovasc Imaging; 2012 Oct; 28(7):1841-9. PubMed ID: 22200931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of hemodynamic and stress testing variables in patients undergoing regadenoson stress myocardial perfusion imaging to regadenoson with adjunctive low-level exercise myocardial perfusion imaging.
    Cabrera R; Husain Z; Palani G; Karthikeyan AS; Choudhry Z; Dhanalakota S; Peterson E; Ananthasubramaniam K
    J Nucl Cardiol; 2013 Jun; 20(3):336-43; quiz 344-5. PubMed ID: 23430361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe chronic kidney disease as a predictor of benefit from aminophylline administration in patients undergoing regadenoson stress myocardial perfusion imaging: A substudy of the ASSUAGE and ASSUAGE-CKD trials.
    Rangel MO; Morales Demori R; Voll ST; Wassouf M; Dick R; Doukky R
    J Nucl Cardiol; 2015 Oct; 22(5):1008-18. PubMed ID: 25500799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regadenoson is a safe and well-tolerated pharmacological stress agent for myocardial perfusion imaging in post-heart transplant patients.
    Cavalcante JL; Barboza J; Ananthasubramaniam K
    J Nucl Cardiol; 2011 Aug; 18(4):628-33. PubMed ID: 21626090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of regimented aminophylline use on extracardiac radioisotope activity in patients undergoing regadenoson stress SPECT myocardial perfusion imaging: a substudy of the ASSUAGE trial.
    Ballany W; Mansour K; Morales Demori R; Al-Amoodi M; Doukky R
    J Nucl Cardiol; 2014 Jun; 21(3):496-502. PubMed ID: 24519563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attenuation of the side effect profile of regadenoson: a randomized double-blind placebo-controlled study with aminophylline in patients undergoing myocardial perfusion imaging and have severe chronic kidney disease--the ASSUAGE-CKD trial.
    Doukky R; Rangel MO; Dick R; Wassouf M; Alqaid A; Margeta B
    Int J Cardiovasc Imaging; 2013 Jun; 29(5):1029-37. PubMed ID: 23224354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regadenoson use in chronic kidney disease and end-stage renal disease: A focused review.
    Vij A; Golzar Y; Doukky R
    J Nucl Cardiol; 2018 Feb; 25(1):137-149. PubMed ID: 28653271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pituitary apoplexy after regadenoson myocardial perfusion scan.
    Shetty S; Gnanaraj J; Jayamani Roshan S; El Accaoui R
    J Nucl Cardiol; 2020 Feb; 27(1):336-339. PubMed ID: 30168027
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety and feasibility of regadenoson use for suboptimal heart rate response during symptom-limited standard Bruce exercise stress test.
    Partington SL; Lanka V; Hainer J; Blankstein R; Skali H; Forman DE; Di Carli MF; Dorbala S
    J Nucl Cardiol; 2012 Oct; 19(5):970-8. PubMed ID: 22565239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety and tolerability of regadenoson in patients with end-stage renal disease: the first prospective evaluation.
    Doukky R; Rangel MO; Wassouf M; Dick R; Alqaid A; Morales Demori R
    J Nucl Cardiol; 2013 Apr; 20(2):205-13. PubMed ID: 23239416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of regadenoson myocardial single-photon emission computed tomography in patients with different degrees of renal dysfunction.
    Bhatti S; Hakeem A; Dhanalakota S; Palani G; Husain Z; Jacobsen G; Ananthasubramaniam K
    Eur Heart J Cardiovasc Imaging; 2014 Aug; 15(8):933-40. PubMed ID: 24699324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Regadenoson as a new stress agent in myocardial perfusion imaging. Initial experience in The Netherlands].
    Jager PL; Buiting M; Mouden M; Oostdijk AH; Timmer J; Knollema S
    Rev Esp Med Nucl Imagen Mol; 2014; 33(6):346-51. PubMed ID: 24862658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of body mass index and type of low-level exercise on the side effect profile of regadenoson.
    Salgado-Garcia C; Jimenez-Heffernan A; Lopez-Martin J; Molina-Mora M; Aroui T; Sanchez de Mora E; Ramos-Font C; Rivera de Los Santos F; Ruiz-Frutos C
    Eur J Nucl Med Mol Imaging; 2017 Oct; 44(11):1906-1914. PubMed ID: 28547175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regadenoson versus Dipyridamole: A Comparison of the Frequency of Adverse Events in Patients Undergoing Myocardial Perfusion Imaging.
    Amer KA; Hurren JR; Edwin SB; Cohen G
    Pharmacotherapy; 2017 Jun; 37(6):657-661. PubMed ID: 28475259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and tolerability of regadenoson in 514 SPECT MPI patients with and without coronary artery disease and submaximal exercise heart rate response.
    AlJaroudi WA; Alraies MC; Cerquiera MD; Jaber WA
    Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):341-8. PubMed ID: 23208701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of regadenoson stress testing in patients with pulmonary hypertension.
    Moles VM; Cascino T; Saleh A; Mikhova K; Lazarus JJ; Ghannam M; Yun HJ; Konerman M; Weinberg RL; Ficaro EP; Corbett JR; McLaughlin VV; Murthy VL
    J Nucl Cardiol; 2018 Jun; 25(3):820-827. PubMed ID: 27896702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attenuation of the side effect profile of regadenoson: a randomized double-blinded placebo-controlled study with aminophylline in patients undergoing myocardial perfusion imaging. "The ASSUAGE trial".
    Doukky R; Morales Demori R; Jain S; Kiriakos R; Mwansa V; Calvin JE
    J Nucl Cardiol; 2012 Jun; 19(3):448-57. PubMed ID: 22395779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ST Segment Elevation ECG Changes During Pharmacologic Stress With Regadenoson.
    Qamruddin S; Huang HW; Mehra A; Bonyadlou S; Yoon AJ
    Clin Nucl Med; 2016 Jan; 41(1):62-4. PubMed ID: 26447370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A useful and easy to develop combined stress test for myocardial perfusion imaging: Regadenoson and isometric exercise, preliminary results.
    Janvier L; Pinaquy J; Douard H; Karcher G; Bordenave L
    J Nucl Cardiol; 2017 Feb; 24(1):34-40. PubMed ID: 26542990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.